<< Stryker adopts quarterly dividend payment policy | Avicenna's work on respiratory diseases highlighted in SAGE journal >>

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

Published on October 30, 2009 at 9:24 AM · No Comments

VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.

The presentation details are as follows: Date / Time: Tuesday November 3, 2009 4:20 pm ET Location: InterContinental Hotel, Boston, MA Track: Targeting Diabetes with Novel Therapeutics - Strategically Advancing Clinical Compounds Title: Liver Directed Beta Agonist for Targeting Cardio- metabolic Disease

In addition, Dr. Taub will participate in other forums on Wednesday November 4, 2009, including a panel on the "Clinical Landscape for New Diabetes Drug Candidates".

SOURCE VIA Pharmaceuticals, Inc.

dc3e11a9-733c-4c48-b4a8-fee8ef8f3d97|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Atherosclerosis, Biotechnology, Cardiometabolic, Cardiovascular Disease, Cholesterol, Diabetes, Dyslipidemia, Hypercholesterolemia, Insulin, Metabolism, Obesity, Stroke, Triglyceride, Type 2 Diabetes, Weight Loss

Related posts

Intervention programs can help teen girls achieve long-term success in managing weightTeenage girls gained less weight, improved their body image, ate less fast food, and had more family...
New cERD method can detect RNAi activity in biological fluidsAlnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that its scienti...
WHO approves three Mylan ARV therapies to treat HIV/AIDSMylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received approval for ...
Viewpoints: Advice for the super committee and pundits; Calif. health insurance regulation; NEJM on episodic paymentAs a member of the Bipartisan Policy Center's Debt Reduction Task Force, I supported gradually raisi...
Merck Serono to present Erbitux data at ESMO CongressMerck Serono, a division of Merck KGaA, Darmstadt, Germany announces today that it will be presentin...
Amarin reports cash balance of $44 million for first-quarter 2010Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular di...
DNA modification can define early onset glioblastomaA class of brain tumor that tends to emerge in younger patients but is less aggressive than others c...
FDA warns patients and physicians about the efficacy of Plavix treatmentThe U.S. Food and Drug Administration today added a boxed warning to the anti-blood clotting drug Pl...
Wisconsin rural hospitals hope for federal money to offset state Medicaid cutWisconsin's rural hospitals hope to offset a state Medicaid cut with a tax that would bring more fed...
Merck discontinues MK-1903 niacin receptor agonist development program with Arena PharmaceuticalsArena Pharmaceuticals, Inc. announced today Merck and Co., Inc.'s decision (through an affiliate) to...
Link found between mitochondria and tumor formation in stem cellsResearchers report on a previously unknown relationship between stem cell potency and the metabolic ...
Measures that are needed to curb humanity's most fatal diseasesSeveral of the world's most eminent health scientists and organizations today publish a landmark glo...
School physical education programs are the place to score in the battle with obesityResearchers from the School of Human Movement Studies at UQ, believe the focus of school physical ed...
International adult stem cell 'retraining' project starts in BirminghamAn exciting research project to utilise the body's own stem cells to regenerate areas of tissue dama...
Fish oil reduces heart attack and blood vessel diseaseFish oil can help reduce deaths from heart disease, according to new evidence reports announced toda...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.